biOasis Technologies Inc. is a Vancouver-based biopharmaceutical company engaged in the development and commercialization of technologies for the diagnosis and treatment of central nervous system (CNS) disorders. Valued at more than US$98B, the CNS market segment is the second-largest category in the pharmaceutical industry and is growing at approximately 8% per annum. The World Health Organization has declared that CNS disorders represent the major medical challenge of the 21st century.
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
The Life Sciences Report Interview with William Gregozeski
"biOasis Technologies Inc. has an Alzheimer's disease test in development that looks very promising and could be ready to license out. That would be an interesting story alone, but given what the company has in its Transcend platform, the Alzheimer's CogniTest has taken a back seat. . .we should see final results from CogniTest preclinical testing later this year. . .the biOasis Transcend platform is a way to take drugs into the brain to target different diseases. BiOasis is developing a protein called p97 (melanotransferrin), which passes through the blood-brain barrier on its own, as few other molecules can. The company has been able to attach or conjugate small and large molecules to this carrier and has been able to ferry these molecules into the brain. The hypothesis is that this could be the way to treat many brain diseases. The company has done testing on several different conjugates, and each one shows that there is a significant increase in uptake versus the drug alone.
"A lot of the work the company has done and announced recently is on Herceptin (trastuzumab), for HER2/neu-positive breast cancer, where metastasis to the brain is a significant problem. BiOasis' conjugate makes the drug work better. Not only that, but from the drug manufacturer's perspective, it's a new compound that can be repatented to extend the life and protection on the drug. The platform doesn't only help the patient; it is a huge financial incentive to the owner of the therapy because it could greatly extend the drug's exclusivity."
William Gregozeski, Mont Blanc Capital Management
"Last week, biOasis Technologies Inc. announced results from its most recent Texas Tech study on BT2111, which showed a 68% reduction in the number of metastatic human HER2+ breast cancer tumors in the brains of test animals compared to the control group over the two-week treatment period; Herceptin alone showed no reduction in the number of tumors. . .with these results, we believe the next step for BT2111 would be entering into a licensing agreement with Roche, whereby Roche would take control of the BT2111 conjugate and move forward with phase 1 clinical trials."
The Life Sciences Report Interview with Jim Letourneau
"I follow a company called biOasis Technologies Inc., which has a $63M market cap. The company's programs came out of research at the University of British Columbia with a protein called p97. This protein moves across the blood-brain barrier easily. To capitalize on this, biOasis is working to conjugate drugs to the p97 protein.
So far all of the data comes from mouse studies, but that has been enough to get big pharma interested. . .biOasis is trying to create as much competitive tension as possible between the different pharmaceutical companies while, at the same time, trying to optimize its technology. It will be interesting to see how this plays out. . .one example involves Herceptin (trastuzumab), marketed by Roche Holding AG , to treat HER2-positive breast cancer. BiOasis has had good results showing that when Herceptin is conjugated with p97, it gets into the brain. Apparently that type of breast cancer spreads to the brain fairly quickly, so there's some excitement around the observations that, in mouse models, the Herceptin conjugate gets into the brain."
biOasis Technologies Inc. Content
Back to Top